EFV (efavirenz) and β-thujaplicinol [2,7-dihydroxy-4-1(methylethyl)-2,4,6-cycloheptatrien-1-one] have contrasting effects on the RNase H activity of HIV-1 RT (reverse transcriptase). EFV binds in the non-nucleoside inhibitor-binding pocket and accelerates this activity, whereas β-thujaplicinol binds in the RNase H active site and inhibits it. We have used pre-steadystate kinetic analyses to gain an insight into the mechanism by which EFV and a β-thujaplicinol analogue [19616 (2,7-dihydroxy-2,4,6-cyclo-heptatrien-1-one)] modulate RT RNase H activity. Our data show that EFV and 19616 have no effect on polymerase-dependent RNase H cleavages. However, both compounds significantly affected the rates of polymeraseindependent RNase H cleavages. In regard to the latter, we found no evidence that the bound RNA/DNA template/primer substrate restricted 19616 from interacting with RT. In light of these data, we propose a model in which 19616 binds to the RNase H active site of RT after the primary polymerase-dependent RNase H cleavage has occurred and stabilizes the 3 -end of the DNA primer in the polymerase active site thus blocking the enzyme's ability to carry out the polymerase-independent cleavages. By contrast, EFV destabilizes the 3 -end of the DNA primer in the DNA polymerase active site and promotes RT-mediated polymeraseindependent cleavages. Consistent with this model, we show antagonism between EFV and 19616.
INTRODUCTION
RT (reverse transcriptase) facilitates the conversion of the HIV-1 single-stranded RNA genome into double-stranded DNA. HIV-1 RT is a multifunctional enzyme that exhibits an RNA-and DNA-dependent DNA polymerase activity, and RNase H activity. Owing to its crucial role in viral replication, RT is a major target for chemotherapeutic intervention. To date, two distinct groups of RT inhibitors have been approved by the US Food and Drug Administration for the treatment of HIV-1 infection. These include: (i) the nucleoside/nucleotide RT inhibitors that bind to the active site of RT and act as competitive inhibitors of DNA polymerization; and (ii) the NNRTIs (non-nucleoside RT inhibitors) that bind to the NNRTI-binding pocket and act as allosteric inhibitors of DNA polymerization.
Although the RNase H activity of RT has been shown to be essential for virus infectivity, very few inhibitors of this activity have been identified and none have progressed to clinical trials. However, over the past few years, significant progress has been made in identifying and characterizing new RNase H inhibitor pharmacophores [1] . For example, β-thujaplicinol [2,7-dihydroxy-4-1(methylethyl)-2,4,6-cycloheptatrien-1-one] was identified as a potent and selective HIV-1 RNase H inhibitor via high-throughput screening of a National Cancer Institute library of pure natural products [2] . Importantly, crystal structures of β-thujaplicinol in complex with RT and an isolated RT-RNase H domain fragment confirmed that it bound in the RNase H active site of the enzyme [3] . However, the mechanism by which β-thujaplicinol inhibits the RNase H activity of HIV-1 RT has not been well defined. Beilhartz et al. [4] demonstrated that β-thujaplicinol is unable to inhibit RNase H cleavage if added after the RT-T/P (template/primer) substrate complex is formed, suggesting that the RNA/DNA substrate may block its access to the RNase H active site. In contrast, Himmel et al. [3] provided biochemical evidence that the presence of a bound RNA/DNA T/P substrate is necessary to achieve its maximal binding to HIV-1 RT. Interestingly, several studies have demonstrated that NNRTIs such as EFV (efavirenz) can accelerate the enzyme's RNase H activity [5] [6] [7] . This is surprising given that the NNRTI-binding pocket is located >50 Å (1 Å = 0.1 nm) away from the RNase H active site of HIV-1 RT. FRET-based single-molecule studies suggested that NNRTIs may affect the orientation of RT on the polypurine tract RNA/DNA hybrid and increase RNase H activity [8] . Recently, Lapkouski et al. [9] solved the structure of HIV-1 RT containing an RNA/DNA hybrid and EFV. The enzyme and RNA/DNA structures in this complex differ from all nucleic acid-RT complexes previously reported. Specifically, the DNA polymerase active site is disengaged from catalysis, whereas the RNA/DNA duplex has ready access to the RNase H active site. Taken together, the single molecule and crystallography studies suggest that NNRTIs lock the RT enzyme in an RNase H competent mode.
Cleavage of RNA/DNA hybrids by RNase H can be accomplished through two different modes of HIV-1 RT binding. The first mode of cleavage is directed by the 3 -end of the elongating plus-strand DNA and is thought to occur in concert with DNA polymerization (i.e. polymerase-dependent RNase H cleavage). A second mode of RNase H cleavage, directed by the 5 -end of the RNA in the RNA/DNA hybrid, presumably allows further degradation of small RNA fragments that remain annealed to the newly synthesized plus DNA strand after DNA 3 -end-directed RNase H cleavage (i.e. polymerase-independent Abbreviations used: EFV, efavirenz; NNRTI, non-nucleoside reverse transcriptase inhibitor; RT, reverse transcriptase; T/P, template/primer; WT, wild-type. 1 To whom correspondence should be addressed (email nps2@pitt.edu).
RNase H cleavage). To gain an insight into the mechanism by which β-thujaplicinol and EFV modulate the RNase H activity of HIV-1 RT, we have systematically assessed their affect on the polymerase-dependent and -independent cleavages of HIV-1 RT using the pre-steady-state kinetic approach.
EXPERIMENTAL

Materials
WT (wild-type) and N348I HIV-1 RT were overexpressed and purified to homogeneity as described previously [10, 11] . RT concentration was determined spectrophotometrically at 280 nm using an absorbance coefficient of 260 450 M − 1 ·cm − 1 . The 7-hydroxy tropolone derivatives 19616 (2,7-dihydroxy-2,4,6-cyclo-heptatrien-1-one), 19617 (2,7-dihydroxy-4-methyl-2,4,6-cyclo-heptatrien-1-one), β-thujaplicinol and 19619 (2,7-dihydroxy-6-methyl-2,4,6-cyclo-heptatrien-1-one) were purchased from Molecular Diversity Preservation International. 32 P]ATP were acquired through Fisher Scientific and PerkinElmer Life Sciences respectively. The DNA and RNA oligonucleotides were synthesized and purified by Integrated DNA Technologies. All other reagents were of the highest quality available and were used without further purification.
T/P substrates
The following RNA/DNA T/P substrates were used in the present study: first, an 18 nt RNA template (RNA-18T: 5 -GAUCUGAGCCUGGGAGCU-3 ) annealed to an 18 nt primer (DNA-18T: 5 -AGCTCCCAGGCTCAGATC-3 ), as described previously [12] . For FRET-based assays, fluorescein and IowaBlack FQ TM were covalently attached to the 3 -and 5 -termini of the RNA and DNA oligonucleotides respectively. For denaturing gel-based assays, the RNA was 5 -radiolabelled with [γ -32 P]ATP as described previously [7] . Secondly, a 26 nt DNA primer (DNA-26P; 5 -CCTGTTCGGGCGCCACTGCTAGA-GAT-3 ) annealed to a 35 nt 5 -32 P-labelled RNA template (RNA-35T; 5 -AGAAUGGAAAAUCUCUAGCAGUGGCGCCCGAA-CAG-3 ). Thirdly, DNA-26P annealed to a 27 nt 5 -32 P-labelled RNA template (RNA-27T; 5 -AGAAUGGAAAAUCUCUA-GCAGUGGCGC-3 ).
FRET-based RNase H cleavage assays
The FRET-based RNase H cleavage assays were carried out as described previously [7] . Fluorescence was measured with a SpectraMax M2 microplate spectrofluorometer (Molecular Devices) using an excitation wavelength of 490 nm and an emission wavelength of 528 nm. Data were analysed using SoftMax Pro software (Molecular Devices). The concentration of each 7-hyroxy-tropolone analogue required to inhibit RNase H cleavage by 50% (i.e. IC 50 ) was calculated using non-linear regression analyses (SigmaPlot Software Version 11, Systat Software) from at least three independent experiments.
Steady-state RNase H cleavage assays
Steady-state RNase H cleavage was examined using both fixed-time dose-response assays and time-course experiments.
In a typical experiment, 400 nM RT was diluted in 50 mM Tris/HCl, pH 7.5, 50 mM KCl and 20 mM MgCl 2 . Reactions were initiated by the addition of an equal volume of 40 nM T/P in 50 mM Tris/HCl, pH 7.5, and 50 mM KCl. Reactions were quenched at appropriate times with gel-loading buffer. RNase H cleavage products were resolved using denaturing PAGE. Product formation was analysed by phosphorimaging using a GS-525 Molecular Imager and Quantity One Software (Bio-Rad Laboratories). The concentration of 19616 required to inhibit RNase H cleavage by 50 % or the concentration of EFV required to enhance RNase H cleavage by 50 % was calculated by nonlinear regression analyses (SigmaPlot Software Version 11, Systat Software).
Pre-steady-state RNase H cleavage assays
Pre-steady-state experiments were carried out using a Kintek RQF-3 rapid quench instrument (Kintek Corporation). In a typical experiment, 400 nM RT was pre-incubated with 40 nM 5 -[
32 P]RNA/DNA T/P in 50 mM Tris/HCl, pH 7.5, 50 mM KCl and 2 mM EDTA prior to mixing with an equivalent volume of 50 mM Tris/HCl, pH 7.5, 50 mM KCl and 22 mM MgCl 2 . Reactions were quenched with 50 mM EDTA, pH 8.0, at times ranging from 25 ms to 120 s. Samples were further analysed as described above.
RESULTS AND DISCUSSION
Structure-activity relationships for the inhibition of HIV-1 RT RNase H activity by 7-hydroxy-tropolone analogues
We first assessed the inhibitory activity of β-thujaplicinol and three related 7-hydroxy-troplone analogues (19616, 19617 and 19619) towards HIV-1 RT RNase H activity ( Figure 1 ) using a FRET-based assay as described previously [12] . β-Thujaplicinol inhibited RT RNase H activity with an IC 50 value of 1.0 + − 0.3 μM. The IC 50 values of 19616 and 19617 were similar to β-thujaplicinol (1.1 + − 0.2 μM and 2.0 + − 0.3 μM respectively). In contrast, 19619 was less active (IC 50 = 15.6 + − 5.6 μM). The available crystal structure data show that β-thujaplicinol primarily interacts with the RNase H active site of RT through co-ordination of the metal ions (all three oxygen atoms of the tropolone ring of β-thujaplicinol co-ordinate the metal ions) and that there are very few interactions between the tropolone ring and the amino acid residues of HIV-1 RT [3] . Consequently the chemical changes at position 5 of the tropolone ring in 19616 and 19617 have a minimal effect on the activity of these analogues. However, there is a non-covalent interaction between the carbon at position 3 of the tropolone ring and His 539 of RT [3] , and the introduction of a methyl group at this position probably impedes inhibitor binding via a steric clash. Owing to the availability of samples, 19616 was used in all further experiments. There is discrepancy in the literature in regard to the mechanism by which β-thujaplicinol inhibits HIV-1 RT RNase H activity. Beilhartz et al. [4] suggested that the inhibitor is unable to bind to a preformed RT-RNA/DNA complex. In contrast, Himmel et al. [3] revealed that β-thujaplicinol can bind to the RT-RNA/DNA complex to form an RT-DNA/RNA-inhibitor complex. The T/P substrate used in these studies differed. Beilhartz et al. [4] used a RNA/DNA substrate with a 22 nt DNA primer recessed at both 5 -and 3 -ends annealed to a 52 nt RNA template. HIV-1 RT can simultaneously engage this substrate at both the DNA polymerase and RNase H active sites of RT and the primer can be extended if the next correct dNTP is added. As such, the first RNase H cleavage is polymerase-dependent. Himmel et al. [3] used the double-stranded 18 nt RNA/DNA duplex substrate described in our FRET assays and depicted in Figure 2 (A). This T/P substrate cannot simultaneously engage both active sites of RT and therefore the first RNase H cleavage is polymeraseindependent. In light of these studies, we next assessed the ability of 19616 and EFV to affect the RNase H activity of HIV-1 RT on different RNA/DNA T/P substrates using pre-steady-state kinetics, as described below.
First, we assessed HIV-1 RT RNase H activity on the bluntended 18 nt RNA/DNA duplex substrate (Figure 2 ). Our data show that 19616 can inhibit cleavage of the RNA irrespective of the order of substrate addition (Figures 2B-2D) . Similarly, EFV enhances RNA cleavage in a manner that is also independent of the order of substrate addition. These findings are consistent with those of Himmel et al. [3] and strongly suggest the formation of RT-RNA/DNA-inhibitor complexes under the assay conditions.
We further assessed HIV-1 RT RNase H activity on a T/P with an RNA/DNA duplex length of 25 nt ( Figure 3A) . We have used this T/P substrate in multiple studies and have clearly delineated the RT RNase H-mediated cleavage events in both the absence and the presence of EFV under steady-state assay conditions [7, 13, 14] . However, we had not previously characterized the ability of an RNase H inhibitor to block the polymerase-dependent and -independent cleavages of HIV-1 RT on this T/P substrate. Therefore we first assessed the ability of 19616 to inhibit HIV-1 RT RNase H activity using a fixed time assay under steady-state conditions ( Figure 3B ). Our data show that 19616 inhibited the secondary RNase H cleavages that reduced the RNA template to 19 nt in length. However, we found no evidence of inhibition of the primary RNase H cleavage event (i.e. there was no accumulation of the full-length 35 nt RNA template with increasing drug concentration). Quantitative analysis of the formation of the 19 nt product yielded an IC 50 value of 0.27 μM for 19616 (results not shown). Consistent with previous studies [7, 13, 14] , EFV enhanced the formation of the 19 nt product (IC 50 = 14.1 nM; results not shown). To assess directly the affect of 19616, EFV and combinations of both inhibitors on the primary and secondary RNase H cleavages of RT we performed presteady-state kinetic analyses using a timescale from 25 ms to 90 min (Figure 4) . The primary polymerase-dependent RNase H cleavage occurred rapidly and more than 80 % of the substrate was cleaved within 25 ms (Figures 4A and 4B ). Despite this, we saw no evidence that either 19616 or EFV affected the primary cleavage event (Figures 4A and 4B) . We also carried out presteady-state kinetics experiments in which the RT-MgCl 2 -EFV (or RT-MgCl 2 -19616) complex was mixed with the T/P substrate. Under these conditions, the initial rate of RNase H cleavage was slowed; however, we again saw no evidence that either 19616 or EFV affected RNase H cleavage (results not shown). However, the rates of the secondary RNase H cleavage events were significantly affected by both 19616 and EFV ( Figure 4C ). In reactions carried out with 19616, there was accumulation of the primary RNase H cleavage products (28 and 27 nt respectively) and the rates of formation of the secondary RNase H cleavage products at 25 nt, 21 nt and 19 nt were significantly decreased compared with the control (i.e. no drug). In contrast, all of these secondary cleavage events occurred much faster when EFV was added to the reaction. Interestingly, when both drugs were combined there was evidence of antagonism: the final RNase H cleavage pattern was similar to the control reaction ( Figure 4C ). Consistent with the data shown in Figure 2 , the ability of 19616 and/or EFV to modulate the polymerase-independent RNase H cleavage activity of HIV-1 RT was independent of the order of substrate addition (results not shown).
Taken together, these data show that both 19616 and EFV have a minimal effect on the primary (DNA polymerase-dependent) RNase H cleavage events of HIV-1 RT, but that both compounds significantly affect the secondary (DNA polymerase-independent) cleavages.
Effect of the N348I mutation in HIV-1 RT on the activity of 19616 and EFV
The N348I mutation in the connection domain of HIV-1 RT confers zidovudine and EFV resistance [15] [16] [17] . Previous studies have demonstrated that the N348I mutation decreases the frequency of secondary polymerase-independent RNase H cleavages by promoting RT to preferentially bind T/P substrates with an RNA/DNA duplex length of 18 nt or less in a polymerasecompetent mode (i.e. the 3 -end of the DNA primer is in the DNA polymerase active site and the RNA/DNA duplex does not extend into the RNase H active site and therefore polymerase-independent RNase H cleavages cannot occur) [15, 17] . Importantly, previous studies have shown that the N348I mutation in HIV-1 RT significantly decreases the ability of NNRTI to accelerate the rates of the polymerase-independent RNase H cleavages [13, 14] . To assess whether 19616 preferentially inhibited N348I RT (compared with WT RT) we performed 19616 and EFV RNase H cleavage dose-response assays using a T/P substrate identical in sequence with that described in Figure 3(A) , except that the 3 -end of the RNA was recessed, mimicking the product that results from polymerase-dependent RNase H cleavage ( Figure 5A ). The data ( Figure 5B) show that the IC 50 value for 19616 for N348I HIV-1 RT (6.1 + − 0.44 μM) is 2.5-fold less than the IC 50 for WT HIV-1 RT (15.17 + − 3.20 μM). In contrast, N348I HIV-1 RT exhibited significantly less polymeraseindependent RNase H cleavage products (as quantified by the 19 nt band) than the WT enzyme ( Figure 3C ). Taken together, these data suggest that 19616 exhibits a greater capacity to inhibit the N348I enzyme that binds recessed RNA/DNA T/P substrates in a DNA polymerase competent mode.
Mechanism by which 19616 and EFV modulate HIV-1 RT RNase H cleavage activity
The results of the present study clearly demonstrate that 19616 does not inhibit the primary polymerase-dependent RNase H cleavage activity of HIV-1 RT. Structural overlay of the crystal structure of HIV-1 RT in complex with β-thujaplicinol (PDB code 3IG1) with RT in complex with an RNA/DNA T/P that occupies the RNase H active site (PDB code 4B3O) shows that the inhibitor and RNA/DNA duplex cannot simultaneously bind in the RNase H active site of RT. The RNA strand in the RNA/DNA duplex occupies the same space as β-thujaplicinol ( Figure 6A ). This finding is consistent with that of Bielhartz et al. [4] who reported that the RNA/DNA substrate may block β-thujaplicinol access to the RNase H active site. However, once the primary RNase H cleavage event has occurred, 19616 can bind to the RT-T/P complex and form an RT-T/P-inhibitor complex that prevents RT from translocating (or dissociating and re-binding) to bind the T/P in a manner that supports the secondary polymeraseindependent RNase H cleavages ( Figure 6B ). This model is consistent with the finding that β-thujaplicinol binds to HIV-1 RT in complex with a blunt-ended 18 nt RNA/DNA T/P substrate [3] , and with the results of the present study which show that the order of substrate addition does not affect the ability of 19616 to inhibit the polymerase-independent cleavages of HIV-1 RT and that N348I RT is hypersusceptible to inhibition by 19616. In contrast, EFV binding to RT destabilizes the 3 -end of the DNA primer in the polymerase active site, favouring polymerase-independent RNase H cleavage [7, 9] . Consistent with this model, we have shown antagonism between EFV and 19616 ( Figure 4C ).
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